Can Loxo Oncology Inc (LOXO) Candidate Larotrectinib Pass Regulatory Test?

Loxo Oncology Inc (NASDAQ:LOXO) is targeting to file for regulatory approval of its gene mutation cancer drug candidate larotrectinib at the end of next year or early in 2018.

Keep Reading →